ReviewPharmacological reviews2025
5-HT
Review in Pharmacological reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- Deconstruction of lysergic acid diethylamide.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Novel Tetrahydropyridinyl-6,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- The Potential of Cannabidiol for the Treatment of Psychosis: Endocannabinoid Regulation of Serotonergic Neurotransmission via Serotonin 5-HT1A/2A Receptors.Neurochemical research · 2026Review
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.CNS drugs · 2026Review
- Novel Compounds as 5‑HT2A Agonists for Treating Mental Illness or CNS Disorders.ACS medicinal chemistry letters · 2026Article
- Novel 6,5-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Natural Products as GPCR-Targeting Antidepressant Candidates: Advances and Opportunities.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Developmental and cell type-specific contributions of thalamic serotonin 2A receptors to absence seizures.Epilepsia · 2026Article
- Integrated 5-HTMolecular psychiatry · 2026Article
- Epigenetic landscapes of classical psychedelics and ketamine: molecular mechanisms of long-lasting neuromodulation.Molecular psychiatry · 2026Review
- Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin.bioRxiv : the preprint server for biology · 2026Article
- Novel 5,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.ACS chemical neuroscience · 2026Review
- Novel Tricyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders.ACS medicinal chemistry letters · 2026Article
- Pretreatment with the psychedelic DOI mitigates LPS-induced hippocampal inflammation and behavioral impairments in mice.BMC neuroscience · 2026Article
- Ibogalogs Activate the 5-HTNeurochemical research · 2026Article
- Unusual experiences and early-onset psychosis associated to hallucinogen use in adolescents: a systematic review and meta-analysis.Child and adolescent psychiatry and mental health · 2026Review
- Psychedelic research must be grounded in pharmacology.Nature neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serotonin 5-HT
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.